Landmark agreement on EU pharma package sets stage for new access and innovation rules

The Council of the European Union and the European Parliament have reached a provisional agreement on the long-anticipated “pharma package,” concluding months of trilogue negotiations and setting in motion the first major overhaul of EU medicines legislation in more than two decades. The deal comes at a moment of heightened scrutiny over drug pricing and increasing concern that Europe is losing ground in pharmaceutical innovation. Policymakers have sought to produce a framework that expands patient access, strengthens supply resilience and supports the competitiveness of the region’s life sciences sector.

The European Commission first proposed the reform in April 2023, with the Council adopting its negotiating mandate in June 2025. Agreement on the final shape of the reforms was reached on December 11, 2025. Danish Health Minister Sophie Løhde said the package “demonstrates the EU’s commitment to both innovation and to ensuring that patients in Europe have access to the medicines they need,” noting improved incentives for priority antibiotics and steps to reduce regulatory burdens. In its statement, the European Commission reinforced that “these measures will substantially strengthen a sector that is vital for the EU’s strategic autonomy. Reform of the pharmaceutical legislation is a key part of the Commission’s agenda… complemented by the Critical Medicines Act, the Life Sciences Strategy and the upcoming Biotech Act.” Olivér Várhelyi, Commissioner for Health and Animal Welfare, added that “most importantly, it will ensure that safe and effective medicines and modern treatments are available to EU patients across our Union.”

Key components of the agreement include:

Regulatory protection framework: The agreement introduces a revised model combining 8 years of regulatory data protection with 1 year of market protection, with extensions available when specific criteria are met. Additional protection may be granted when a product addresses unmet medical need, incorporates comparative evidence across multiple Member States or meets timelines for global filings. A further extension applies when new indications demonstrating significant clinical benefit are authorized during the protection window. Total protection is capped at 11 years.

Expanded Bolar provisions: The updated Bolar exemption confirms that patent and supplementary protection certificate (SPC) rights are not infringed when manufacturers conduct studies, trials or other preparatory work needed for market entry. This includes activities to support marketing authorizations, HTA procedures, pricing and reimbursement submissions and tender applications, provided no sale or offering for sale occurs during the protection period.

Orphan medicines pathway: For rare diseases, “breakthrough” orphan medicinal products, those treating conditions with no authorized therapy and showing clinically relevant benefit, may receive up to 11 years of market exclusivity. The agreement also preserves the EU’s public register of designated orphan medicines, managed by the EMA, to support transparency.

Modernized regulatory processes: As noted in the EMA’s press release, the reforms streamline EMA operations by consolidating five human medicines committees into two, the Committee for Human Medicinal Products (CHMP) and the Pharmacovigilance Risk Assessment Committee (PRAC), supported by strengthened expert input and increased patient and healthcare professional representation. This leaner structure is expected to shorten assessment timelines from 210 to 180 days and free scientific capacity for enhanced pre-authorization support. The package also accelerates digitalization, requiring companies to submit applications in electronic, structured formats and provide approved product information electronically (ePI). In addition, the Commission, advised by the EMA, may establish regulatory sandboxes to support the development and testing of novel therapies, alongside adapted regulatory frameworks for non-standard categories, including personalized medicines that could substantially improve patient access and care.

EMA Executive Director Emer Cooke noted these regulatory changes will help the Agency operate “more efficiently while maintaining scientific rigor,” adding that the updated processes will better support innovation and help new treatments reach patients sooner.

Safeguards for medicine availability: The final text retains a provision allowing Member States to require companies to supply medicines benefiting from regulatory protection in sufficient quantities to meet patient needs. Safeguards were added to prevent misuse, particularly to avoid facilitating parallel trade. The package also strengthens EU-level monitoring of shortages, expands company obligations and establishes an EU list of critical medicines supported by vulnerability assessments.

Incentives for antimicrobial innovation: To stimulate the development of priority antibiotics, negotiators agreed on transferable exclusivity vouchers granting an additional year of protection for another product in a company’s portfolio. Use of the vouchers will be restricted by a “blockbuster clause,” preventing their application to products with annual sales exceeding €490 million to manage potential budget impact.

Industry reactions so far reflect cautious relief. Troels Rye-Andersen of Novo Nordisk said that “considering where we started, with an anti-industry proposal from the European Commission, it is great news that the parties in the trilogue negotiations concluded on a moderated version which at least does not take Europe as much backwards as we feared.” EFPIA also welcomed the broader policy package, including the upcoming Biotech Act, but cautioned that the compromise does not fully address Europe’s declining competitiveness.

Patient organizations offered broadly positive assessments. The Association of European Cancer Leagues said it “broadly welcomes the deal,” highlighting progress in addressing gaps in access to safe, effective and affordable medicines for cancer patients across the EU. The European Patients’ Forum similarly praised the agreement, particularly the confirmation of patient membership and voting rights within the CHMP. The organization said it was “proud to have demonstrated to EU policymakers the significant added value of patient involvement,” describing the result as the culmination of a coordinated campaign by patient groups across the EU.

The provisional agreement now awaits formal approval by the Parliament and the Council. Once adopted and published in the EU’s Official Journal, attention will turn to implementing guidance, transitional arrangements and how Member States interpret new supply and protection obligations. These details will shape the real-world impact of the reform on access, innovation and market dynamics across the EU.